bioRxiv · 10.1101/2025.10.30.685646
In vitro Characterization of Peptidomimetic Proteolysis Targeting Chimera (PROTAC) as a Degrader of 3-Chymotrypsin-Like Protease (Mpro/3CLpro) against SARS-CoV-2
Abstract
The SARS-CoV-2 main protease (3CLpro) is a key target for antiviral development. We investigated FT235, a peptidomimetic PROTAC linking a GC-376 warhead to pomalidomide for targeted degradation. FT235 bound 3CLpro, inhibiting activity (IC50 = 21.2 {micro}M), and reducing protease levels in cells. In vitro data showed no cytotoxicity up to 100 {micro}M and variant-dependent antiviral activity, with increased potency in the presence of a P-gp inhibitor. These results support PROTAC-based antivirals as promising therapeutic candidates.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Liturri, M. G., Bergna, A., Lai, A., Della Ventura, C., Gabrieli, A., Seravalli, I., Ciofi-Baffoni, S., Lenci, E., Trabocchi, A., Rusconi, S.. 2025-11-03. In vitro Characterization of Peptidomimetic Proteolysis Targeting Chimera (PROTAC) as a Degrader of 3-Chymotrypsin-Like Protease (Mpro/3CLpro) against SARS-CoV-2. https://doi.org/10.1101/2025.10.30.685646
Cite the original work for its findings. Save a collection to share your selection of sources.